Oxycontin LP 10mg ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease1

6. Parkinson disease


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-001523-24-FR
(EUCTR)
25/03/201620/04/2016Evaluation of the pain relief of prolonged-release oxycodone and of L-Dopa, versus placebo, in Parkinson's disease.Evaluation of the analgesic effects of prolonged-release oxycodone and of L-Dopa, versus placebo, on central neuropathic pain in Parkinson's disease : OXYDOPA trial - OXYDOPA Central neuropathic pain in Parkinson's disease
MedDRA version: 19.0;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: oxycontin LP 5mg
Product Name: Oxycontin LP 5mg
INN or Proposed INN: oxycodone
Other descriptive name: OXYCODONE HYDROCHLORIDE
Trade Name: oxycontin LP 10mg
Product Name: Oxycontin LP 10mg
INN or Proposed INN: oxycodone
Other descriptive name: OXYCODONE HYDROCHLORIDE
Trade Name: oxycontin LP 20mg
Product Name: Oxycontin LP 20mg
INN or Proposed INN: oxycodone
Other descriptive name: OXYCODONE HYDROCHLORIDE
Trade Name: Modopar 125
Product Name: Modopar 125
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
INN or Proposed INN: BENSERAZIDE
Trade Name: Modopar 62,5
Product Name: Modopar 62,5
INN or Proposed INN: levodopa
Other descriptive name: LEVODOPA
UHToulouseNULLNot RecruitingFemale: yes
Male: yes
75Phase 2;Phase 3France